Positive correlation between organic anion transporter 1B function indicated by plasma concentration of coproporphyrin-I and blood concentration of cyclosporin A in real-world patients.
3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, coproporphyrin-I, cyclosporin A, organic anion transporter 1B
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
20
10
2022
received:
05
08
2022
accepted:
21
11
2022
medline:
14
4
2023
pubmed:
16
12
2022
entrez:
15
12
2022
Statut:
ppublish
Résumé
Cyclosporin A (CyA) has potent inhibitory activity on organic anion transporting polypeptide 1B (OATP1B), causing drug-drug interactions with its substrate drugs. 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF), a uraemic toxin, has also been suggested to inhibit OATP1B activity. Recent study has identified coproporphyrin-I (CP-I) as a specific endogenous substrate for OATP1B, which is useful to indicate OATP1B activity. We investigated the relationship of CP-I with CyA and CMPF concentrations in patients taking CyA. In total, 121 blood samples from 74 patients who took CyA and underwent routine therapeutic drug monitoring were divided into trough and peak samples. CyA and CP-I concentrations were significantly higher in peak samples than in trough samples. A positive correlation between CP-I and CyA concentrations was found in all samples and in trough and peak samples, while no correlation was observed between CP-I and CMPF concentrations. Multiple regression analysis identified CyA and C-reactive protein concentrations as independent factors affecting CP-I concentration, with blood CyA concentration having markedly greater contribution to plasma CP-I concentration. The present study suggests that CyA inhibits OATP1B activity in a concentration-dependent manner in clinical setting, and that dose adjustment of OATP1B substrate drugs coadministered with CyA according to plasma CMPF concentration may not be necessary.
Substances chimiques
Organic Anion Transporters
0
Cyclosporine
83HN0GTJ6D
Coproporphyrins
0
Liver-Specific Organic Anion Transporter 1
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1672-1681Informations de copyright
© 2022 British Pharmacological Society.
Références
Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693-705. doi:10.1111/j.1476-5381.2009.00430.x
Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006;34(7):1229-1236. doi:10.1124/dmd.106.009290
Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005;77(6):468-478. doi:10.1016/j.clpt.2005.01.018
Nishizato Y, Ieiri I, Suzuki H, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003;73(6):554-565. doi:10.1016/s0009-9236(03)00060-2
Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005;15(7):513-522. doi:10.1097/01.fpc.0000170913.73780.5f
Amundsen R, Christensen H, Zabihyan B, Asberg A. Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metab Dispos. 2010;38(9):1499-1504. doi:10.1124/dmd.110.032268
Mori D, Kimoto E, Rago B, et al. Dose-dependent inhibition of OATP1B by rifampicin in healthy volunteers: comprehensive evaluation of candidate biomarkers and OATP1B probe drugs. Clin Pharmacol Ther. 2020;107(4):1004-1013. doi:10.1002/cpt.1695
Fujita K, Sugiura T, Okumura H, et al. Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans. Pharm Res. 2014;31(1):204-215. doi:10.1007/s11095-013-1153-x
Le Vee M, Lecureur V, Stieger B, Fardel O. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab Dispos. 2009;37(3):685-693. doi:10.1124/dmd.108.023630
Takahashi T, Ohtsuka T, Yoshikawa T, et al. Pitavastatin as an in vivo probe for studying hepatic organic anion transporting polypeptide-mediated drug-drug interactions in cynomolgus monkeys. Drug Metab Dispos. 2013;41:1875-1882. doi:10.1124/dmd.113.052753
Shen H, Chen W, Drexler DM, et al. Comparative evaluation of plasma bile acids, dehydroepiandrosterone sulfate, hexadecanedioate, and tetradecanedioate with coproporphyrins I and III as markers of OATP inhibition in healthy subjects. Drug Metab Dispos. 2017;45(8):908-919. doi:10.1124/dmd.117.075531
Shen H, Dai J, Liu T, et al. Coproporphyrins I and III as functional markers of OATP1B activity: in vitro and in vivo evaluation in preclinical species. J Pharmacol Exp Ther. 2016;357:382-393. doi:10.1124/jpet.116.232066
Jones NS, Yoshida K, Salphati L, Kenny JR, Durk MR, Chinn LW. Complex DDI by fenebrutinib and the use of transporter endogenous biomarkers to elucidate the mechanism of DDI. Clin Pharmacol Ther. 2020;107(1):269-277. doi:10.1002/cpt.1599
Kunze A, Ediage EN, Dillen L, Monshouwer M, Snoeys J. Clinical investigation of coproporphyrins as sensitive biomarkers to predict mild to strong OATP1B-mediated drug-drug interactions. Clin Pharmacokinet. 2018;57(12):1559-1570. doi:10.1007/s40262-018-0648-3
Suzuki Y, Ono H, Tanaka R, et al. Recovery of OATP1B activity after living kidney transplantation in patients with end-stage renal disease. Pharm Res. 2019;36(4):59. doi:10.1007/s11095-019-2593-8
Suzuki Y, Sasamoto Y, Yoshijima C, et al. Simultaneous quantification of coproporphyrin-I and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high performance liquid chromatography coupled to tandem mass spectrometry. J Pharm Biomed Anal. 2020;184:113202. doi:10.1016/j.jpba.2020.113202
Ono H, Tanaka R, Suzuki Y, et al. Factors influencing plasma coproporphyrin-I concentration as biomarker of OATP1B activity in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2021;110(4):1096-1105. doi:10.1002/cpt.2375
Gu X, Wang L, Gan J, et al. Absorption and disposition of coproporphyrin I (CPI) in cynomolgus monkeys and mice: pharmacokinetic evidence to support the use of CPI to inform the potential for organic anion-transporting polypeptide inhibition. Drug Metab Dispos. 2020;48(8):724-734. doi:10.1124/dmd.120.090670
Alexander SP, Kelly E, Marrion NV, et al. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: overview. Br J Pharmacol. 2017;174(Suppl 1):S1-s16. doi:10.1111/bph.13882
Duncan N, Craddock C. Optimizing the use of cyclosporin in allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38:169-174. doi:10.1038/sj.bmt.1705404
Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982-992. doi:10.1053/j.ajkd.2008.12.034
Watanabe T, Tanaka R, Ono H, Suzuki Y, Tatsuta R, Itoh H. Sensitive, wide-range and high-throughput quantification of cyclosporine in whole blood using ultra-performance liquid chromatography coupled to tandem mass spectrometry and comparison with an antibody-conjugated magnetic immunoassay. Biomed Chromatogr. 2021;35(8):e5128. doi:10.1002/bmc.5128
Suzuki Y, Sasamoto Y, Koyama T, et al. Relationship of hemoglobin level and plasma coproporphyrin-I concentrations as an endogenous probe for phenotyping OATP1B. Clin Transl Sci. 2021;14(4):1403-1411. doi:10.1111/cts.12996
Sticova E, Jirsa M. New insights in bilirubin metabolism and their clinical implications. World J Gastroenterol. 2013;19(38):6398-6407. doi:10.3748/wjg.v19.i38.6398
Takehara I, Yoshikado T, Ishigame K, et al. Comparative study of the dose-dependence of OATP1B inhibition by rifampicin using probe drugs and endogenous substrates in healthy volunteers. Pharm Res. 2018;35(7):138. doi:10.1007/s11095-018-2416-3
Yoshikado T, Yoshida K, Kotani N, et al. Quantitative analyses of hepatic OATP-mediated interactions between statins and inhibitors using PBPK modeling with a parameter optimization method. Clin Pharmacol Ther. 2016;100(5):513-523. doi:10.1002/cpt.391
Yee SW, Giacomini MM, Shen H, et al. Organic anion transporter polypeptide 1B1 polymorphism modulates the extent of drug-drug interaction and associated biomarker levels in healthy volunteers. Clin Transl Sci. 2019;12(4):388-399. doi:10.1111/cts.12625
Shitara Y, Nagamatsu Y, Wada S, Sugiyama Y, Horie T. Long-lasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin a in rats. Drug Metab Dispos. 2009;37(6):1172-1178. doi:10.1124/dmd.108.025544
Shitara Y, Sugiyama Y. Preincubation-dependent and long-lasting inhibition of organic anion transporting polypeptide (OATP) and its impact on drug-drug interactions. Pharmacol Ther. 2017;177:67-80. doi:10.1016/j.pharmthera.2017.02.042
Izumi S, Nozaki Y, Lee W, Sugiyama Y. Experimental and modeling evidence supporting the trans-inhibition mechanism for preincubation time-dependent, long-lasting inhibition of organic anion transporting polypeptide 1B1 by cyclosporine a. Drug Metab Dispos. 2022;50(5):541-551. doi:10.1124/dmd.121.000783
Billington S, Shoner S, Lee S, et al. Positron emission tomography imaging of [(11) C]Rosuvastatin hepatic concentrations and hepatobiliary transport in humans in the absence and presence of Cyclosporin a. Clin Pharmacol Ther. 2019;106(5):1056-1066. doi:10.1002/cpt.1506
Mochizuki T, Aoki Y, Yoshikado T, et al. Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs. Clin Transl Sci. 2022;15(6):1519-1531. doi:10.1111/cts.13272
Tan ML, Yoshida K, Zhao P, et al. Effect of chronic kidney disease on nonrenal elimination pathways: a systematic assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP. Clin Pharmacol Ther. 2018;103(5):854-867. doi:10.1002/cpt.807
Sun H, Huang Y, Frassetto L, Benet LZ. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos. 2004;32(11):1239-1246. doi:10.1124/dmd.104.000521
Fujita K, Masuo Y, Okumura H, et al. Increased plasma concentrations of unbound SN-38, the active metabolite of irinotecan, in cancer patients with severe renal failure. Pharm Res. 2016;33(2):269-282. doi:10.1007/s11095-015-1785-0
Kimoto E, Costales C, West MA, et al. Biomarker-informed model-based risk assessment of organic anion transporting polypeptide 1B mediated drug-drug interactions. Clin Pharmacol Ther. 2022;111(2):404-415. doi:10.1002/cpt.2434
Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805-1812. doi:10.1172/jci18921
Suzuki Y, Sasamoto Y, Koyama T, et al. Substantially increased plasma coproporphyrin-I concentrations associated with OATP1B1*15 allele in Japanese general population. Clin Transl Sci. 2021;14(1):382-388. doi:10.1111/cts.12889